Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Psychotic-like experiences in a community sample of adolescents: implications for the continuum model of psychosis and prediction of schizophrenia.

Yung AR, Nelson B, Baker K, Buckby JA, Baksheev G, Cosgrave EM.

Aust N Z J Psychiatry. 2009 Feb;43(2):118-28. doi: 10.1080/00048670802607188.

PMID:
19153919
2.

Neuroanatomical correlates of neurological soft signs in antipsychotic-naive schizophrenia.

Venkatasubramanian G, Jayakumar PN, Gangadhar BN, Keshavan MS.

Psychiatry Res. 2008 Dec 30;164(3):215-22. doi: 10.1016/j.pscychresns.2007.12.021.

PMID:
19019637
3.

Subchronic MK-801 behavioural deficits in rats: partial reversal by the novel nitrate GT 1061.

Beninger RJ, Forsyth JK, Van Adel M, Reynolds JN, Boegman RJ, Jhamandas K.

Pharmacol Biochem Behav. 2009 Feb;91(4):495-502. doi: 10.1016/j.pbb.2008.09.003. Epub 2008 Sep 10.

PMID:
18834899
4.

Brain imaging in pediatric obsessive-compulsive disorder.

MacMaster FP, O'Neill J, Rosenberg DR.

J Am Acad Child Adolesc Psychiatry. 2008 Nov;47(11):1262-72. doi: 10.1097/CHI.0b013e318185d2be. Review.

5.

Schizophrenia, "just the facts": what we know in 2008 Part 3: neurobiology.

Keshavan MS, Tandon R, Boutros NN, Nasrallah HA.

Schizophr Res. 2008 Dec;106(2-3):89-107. doi: 10.1016/j.schres.2008.07.020. Epub 2008 Sep 16. Review.

PMID:
18799287
6.

Emerging drugs for schizophrenia.

Agid O, Kapur S, Remington G.

Expert Opin Emerg Drugs. 2008 Sep;13(3):479-95. doi: 10.1517/14728214.13.3.479 . Review.

PMID:
18764724
7.

Role of glutamate in schizophrenia: integrating excitatory avenues of research.

Sodhi M, Wood KH, Meador-Woodruff J.

Expert Rev Neurother. 2008 Sep;8(9):1389-406. doi: 10.1586/14737175.8.9.1389. Review.

PMID:
18759551
8.

Updated overview of the putative role of the serotoninergic system in obsessive-compulsive disorder.

Aouizerate B, Guehl D, Cuny E, Rougier A, Burbaud P, Tignol J, Bioulac B.

Neuropsychiatr Dis Treat. 2005 Sep;1(3):231-43.

9.

The role of the cerebellum in schizophrenia.

Andreasen NC, Pierson R.

Biol Psychiatry. 2008 Jul 15;64(2):81-8. doi: 10.1016/j.biopsych.2008.01.003. Epub 2008 Apr 8. Review.

10.

Thalamus surface shape deformity in obsessive-compulsive disorder and schizophrenia.

Kang DH, Kim SH, Kim CW, Choi JS, Jang JH, Jung MH, Lee JM, Kim SI, Kwon JS.

Neuroreport. 2008 Apr 16;19(6):609-13. doi: 10.1097/WNR.0b013e3282fa6db9.

PMID:
18382272
11.

Glutamatergic dysfunction--newer targets for anti-obsessional drugs.

Bhattacharyya S, Chakraborty K.

Recent Pat CNS Drug Discov. 2007 Jan;2(1):47-55. Review.

PMID:
18221217
12.

Frontal-subcortical circuitry and behavior.

Bonelli RM, Cummings JL.

Dialogues Clin Neurosci. 2007;9(2):141-51. Review.

13.

Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder.

Dickel DE, Veenstra-VanderWeele J, Cox NJ, Wu X, Fischer DJ, Van Etten-Lee M, Himle JA, Leventhal BL, Cook EH Jr, Hanna GL.

Arch Gen Psychiatry. 2006 Jul;63(7):778-85.

PMID:
16818867
14.

Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders.

Denys D.

Psychiatr Clin North Am. 2006 Jun;29(2):553-84, xi. Review.

PMID:
16650723
15.

A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.

Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF.

Mol Psychiatry. 2006 Jul;11(7):622-32. Epub 2006 Apr 4. Review. Erratum in: Mol Psychiatry. 2006 Aug;11(8):795.

PMID:
16585942
16.

Developmental biomarkers in schizophrenia and other psychiatric disorders: common origins, different trajectories?

Keshavan MS, Diwadkar V, Rosenberg DR.

Epidemiol Psichiatr Soc. 2005 Oct-Dec;14(4):188-93. Review. No abstract available.

PMID:
16396426
17.

Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.

Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, Malison RT, Krystal JH.

Biol Psychiatry. 2005 Sep 1;58(5):424-8.

PMID:
15993857
18.
19.

Glutamatergic dysfunction in OCD.

Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S.

Neuropsychopharmacology. 2005 Sep;30(9):1735-40.

20.

The neurodevelopmental model of schizophrenia: update 2005.

Rapoport JL, Addington AM, Frangou S, Psych MR.

Mol Psychiatry. 2005 May;10(5):434-49. Review.

PMID:
15700048

Supplemental Content

Support Center